TOS / OMA / OAC Expert Guidance Statement on Obesity Pharmacotherapy: A Humbling Call to Action

Documenti analoghi

• Joint TOS / OMA / OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach
  di: Lydia Alexander, et al.
  Pubblicazione: (2026)
• Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice
  di: Hamlet Gasoyan, et al.
  Pubblicazione: (2025)
• Effect of semaglutide 2.4 mg on use of antihypertensive and lipid‐lowering treatment in five randomized controlled STEP trials
  di: Beverly G. Tchang, et al.
  Pubblicazione: (2025)
• Correction to “Defining and Diagnosing Obesity in India: A Call for Advocacy and Action”
  Pubblicazione: (2025)
• Targeting Multiple Gut‐Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy
  di: Alexander D. Miras, et al.
  Pubblicazione: (2026)